Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing therapies for hematologic disorders and cancer. The company markets four products: TAVALISSE (fostamatinib) for chronic immune thrombocytopenia (ITP), GAVRETO (pralsetinib) for RET fusion-positive non-small cell lung cancer and thyroid cancer, REZLIDHIA (olutasidenib) for relapsed or refractory IDH1-mutated acute myeloid leukemia, and VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. Rigel also has a pipeline asset, R289, a dual IRAK1/4 inhibitor in Phase 1b development for lower-risk myelodysplastic syndrome. The company generates additional revenue through collaboration and licensing agreements with international partners including Kissei (Japan), Grifols (global), Knight Therapeutics (Latin America), and Medison Pharma, and holds the global license for VEPPANU through an agreement with Arvinas and Pfizer. Updated Aug 4, 2026